Navigation Links
Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors
Date:9/15/2009

BOSTON, Sept. 15 /PRNewswire/ -- The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion titled "Cardiovascular Disease in Survivors of Childhood Cancer" presented by Dr. Ming Hui Chen, Director, Stress Echocardiography Program and Program for Cardiac Health in Cancer Survivors, Children's Hospital Boston. Dr. Chen's presentation highlights the increased risk of heart failure among childhood cancer survivors due to cancer treatments, highlighting the need for patient-physician education and counseling to monitor and help prevent heart disease.

Heart failure can be difficult to detect and diagnose in adult survivors of childhood cancers since patients may not fit the typical demographic profile of heart failure patients. Childhood cancer survivors are likely to present with heart failure symptoms earlier in their adult life. Females, African-Americans and those that received both radiation and anti-cancer therapy are at greatest risk. Specific side effects of treatment and diseases are dependent upon the type of cancer treatment patients receive.

"It is critical for the public to become aware that there are populations at risk for heart failure outside of the traditional demographic," said Dr. Douglas Mann, HFSA President. "Physical exams and follow up care is important in ensuring disease prevention in these non-traditional groups."

"It takes decades for side effects to occur after cancer treatment, therefore making it harder for physicians to recognize the association between cancer treatment and heart failure," said Dr. Chen. Doctors specializing in late-effects recommend childhood cancer survivors take several preventative measures against heart disease, such as receiving regular screening for several decades after completing cancer therapy as the risk of cardiovascular disease increases with longer follow up, keeping a copy of their own cancer treatment records with them and becoming knowledgeable about their disease and treatment.

"Patients should be encouraged to become their own advocates and educate themselves about their cancer treatments to aide physicians in proper care," said Dr. Chen. "Both awareness and screening is important to ensure early detection of heart failure among childhood cancer survivors or for the opportunity to help modify risk factors of the onset of cardiac events."

Treatments for cancer in the last ten to fifteen years have used lower doses of radiation therapy and anti-cancer agents, thereby potentially reducing the risk of long-term cardiovascular problems in childhood cancer survivors. Additional data will be more forthcoming in the future.

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,500 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.


'/>"/>
SOURCE The Heart Failure Society of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
2. Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
3. Thoratec Presentation at UBS Conference to be Webcast
4. Regeneron Announces September 2009 Investment Conference Presentations
5. NBTY To Web Cast Presentation at CL King Best Ideas Conference; Announces Preliminary Unaudited Net Sales Results For August 2009
6. Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
7. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Haemacure announces its presentation at the Rodman Renshaw 11th Annual Healthcare Conference
9. Volcano Corporation Presentation at Weisel Conference to be Webcast
10. Hospira Receives FDA Approval for Six New Presentations of Heparin
11. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: